Pentwater Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Pentwater Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25,000	Closed	-$453K	–	130
2023 Q2	$453K	Sell	25,000 -15,000	-38%	-$355K	﹤0.01%	118
2023 Q1	$1.06M	Buy	+40,000	New	+$1.14M	0.01%	120
2022 Q1	–	Sell	-60,000	Closed	-$810K	–	199
2021 Q4	$810K	Hold	60,000	–	–	0.01%	180
2021 Q3	$1.01M	Buy	60,000 +30,000	+100%	+$637K	0.01%	186
2021 Q2	$874K	Hold	30,000	–	–	0.01%	222
2021 Q1	$1.18M	Sell	30,000 -10,500	-26%	-$341K	0.01%	211
2020 Q4	$920K	Hold	40,500	–	–	0.01%	166
2020 Q3	$917K	Hold	40,500	–	–	0.01%	166
2020 Q2	$1.31M	Buy	+40,500	New	+$1.07M	0.02%	94

Other funds holding PLRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Pentwater Capital Management's PLRX Position: Q3 2023 in Review

Pentwater Capital Management sold out of Pliant Therapeutics (PLRX) in Q3 2023, closing a stake of 25,000 shares — an estimated $453K sold.

Pentwater Capital Management first reported a position in PLRX in Q2 2020 and held it in 9 quarters. The position peaked at $1.31M in Q2 2020. 136 funds tracked by Wall St. Rank hold PLRX as of Q3 2023.

Pentwater Capital Management reported no remaining Pliant Therapeutics position as of Q3 2023 after selling out during the quarter.
Pentwater Capital Management sold 25,000 Pliant Therapeutics shares in Q3 2023, an estimated $453K.
Pentwater Capital Management first reported a position in Pliant Therapeutics in Q2 2020 and held it in 9 quarters.
Pentwater Capital Management's Pliant Therapeutics position peaked at $1.31M in Q2 2020.
136 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2023.

Based on Pentwater Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.